In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...
This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a ...
Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...
The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...
Significant PrEP underutilization remains, with ~600,000 US users versus an estimated 2.2 million who could benefit, largely due to low awareness, stigma, and misconceptions about HIV risk. Yeztugo is ...
Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...
Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step ...
Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...
PE: What is the reaction to DTC pharma advertising? Donaldson: Consumers will slowly but surely have increased distrust in ...
Otsuka America Pharmaceutical’s president and CEO Tarek Rabah spoke with Pharmaceutical Executive about the company’s mission ...
In today’s Pharmaceutical Executive Daily, the FDA approves Braftovi for mutant metastatic colorectal cancer, Novo Nordisk ...
Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results